Efficacy and Safety of Incretin-Based Anti-Obesity Medications in Adults with Overweight or Obesity: A Systematic Review of Phase 3 Randomized Controlled Trials

Authors

  • Harry Yuseptian Dr. A. Dadi Tjokrodipo Regional Public Hospital Author
  • Fajriza Yona Universitas Prima Nusantara Bukittinggi Author
  • Edwin Danie Olsa Universitas Prima Nusantara Bukittinggi Author

DOI:

https://doi.org/10.35730/c0ahyw36

Keywords:

Obesity, liraglutide, semaglutide, tirzepatide, systematic review, randomized controlled trial

Abstract

Background: Obesity is a major risk factor for cardiometabolic disease. Incretin-based medications (liraglutide, semaglutide, and tirzepatide) have been tested in large phase 3 randomized controlled trials (RCTs). This systematic review summarizes their efficacy and safety in adults with overweight or obesity.

Methods: Peer-reviewed phase 3 placebo-controlled RCTs of liraglutide 3.0 mg, semaglutide 2.4 mg, or tirzepatide in adults with overweight or obesity, with or without type 2 diabetes, were eligible. Data were extracted and synthesized without meta-analysis following the SWiM reporting guideline, with trials grouped by population, and with qualitative risk-of-bias appraisal using RoB 2 domains.

Findings: Six RCTs (SCALE, STEP 1, SURMOUNT-1, STEP 2, SURMOUNT-2, SELECT; 27,983 randomized participants) were included. Without diabetes, mean weight change was −8.4 kg with liraglutide, −14.9% with semaglutide, and −15.0% to −20.9% with tirzepatide, compared with −2.4% to −3.1% with placebo. With type 2 diabetes, weight loss was smaller (semaglutide −9.6%; tirzepatide −12.8% to −14.7%). In SELECT, semaglutide reduced major cardiovascular events in adults with established cardiovascular disease and overweight or obesity (HR 0.80, 95% CI 0.72–0.90). Gastrointestinal adverse events were the main tolerability issue, and discontinuation due to adverse events was higher with active treatment.

Conclusion: Incretin-based medications produce substantial weight loss versus placebo, with the largest effects for tirzepatide, and semaglutide reduced cardiovascular events in one outcome trial. Gastrointestinal tolerability and long-term data remain important considerations.

Downloads

Published

2026-09-30